BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1272 related articles for article (PubMed ID: 21868491)

  • 21. Validation microsatellite path score in a population-based cohort of patients with colorectal cancer.
    Bessa X; Alenda C; Paya A; Álvarez C; Iglesias M; Seoane A; Dedeu JM; Abulí A; Ilzarbe L; Navarro G; Pellise M; Balaguer F; Castellvi-Bel S; Llor X; Castells A; Jover R; Andreu M
    J Clin Oncol; 2011 Sep; 29(25):3374-80. PubMed ID: 21788563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microsatellite instability: an update.
    Yamamoto H; Imai K
    Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma.
    Kaur G; Masoud A; Raihan N; Radzi M; Khamizar W; Kam LS
    Indian J Med Res; 2011 Aug; 134(2):186-92. PubMed ID: 21911971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
    Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
    Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers--ready for prime time?
    Søreide K
    Tumour Biol; 2007; 28(5):290-300. PubMed ID: 17962726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm].
    Schneider R; Schneider C; Büttner R; Reinacher-Schick A; Tannapfel A; Fürst A; Rüschoff J; Jakobeit C; Royer-Pokora B; Möslein G
    Zentralbl Chir; 2015 Dec; 140(6):591-9. PubMed ID: 25372301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
    Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
    J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome.
    van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN;
    J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
    Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
    Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
    Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
    J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer.
    Siraj AK; Prabhakaran S; Bavi P; Bu R; Beg S; Hazmi MA; Al-Rasheed M; Al-Assiri M; Sairafi R; Al-Dayel F; Al-Sanea N; Uddin S; Al-Kuraya KS
    Cancer; 2015 Jun; 121(11):1762-71. PubMed ID: 25712738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
    Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
    Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
    Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors.
    Mensenkamp AR; Vogelaar IP; van Zelst-Stams WA; Goossens M; Ouchene H; Hendriks-Cornelissen SJ; Kwint MP; Hoogerbrugge N; Nagtegaal ID; Ligtenberg MJ
    Gastroenterology; 2014 Mar; 146(3):643-646.e8. PubMed ID: 24333619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
    Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
    Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simplified identification of Lynch syndrome: a prospective, multicenter study.
    Bonnet D; Selves J; Toulas C; Danjoux M; Duffas JP; Portier G; Kirzin S; Ghouti L; Carrère N; Suc B; Alric L; Barange K; Buscail L; Chaubard T; Imani K; Guimbaud R
    Dig Liver Dis; 2012 Jun; 44(6):515-22. PubMed ID: 22480969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
    Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
    Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers.
    Lawes DA; Pearson T; Sengupta S; Boulos PB
    Br J Cancer; 2005 Aug; 93(4):472-7. PubMed ID: 16106253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.